Mar 01, 2021 / 03:20PM GMT
Philip M. Nadeau - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
Good morning, and welcome once again to Cowen and Company's hopefully only virtual health care conference. I'm Phil Nadeau, Biotech Analyst here at Cowen, and it's my pleasure to moderate a fireside chat with Biogen. We have Michel Vounatsos, the CEO of Biogen with us today, as well as AL Sandrock, Executive Vice President of R&D.
Questions and Answers:
Philip M. Nadeau - Cowen and Company, LLC, Research Division - MD & Senior Research AnalystSo maybe over to you for the first question. Can you discuss your vision for Biogen over the next 5 years? How is the company going to create shareholder value? And what do you think differentiates Biogen as an investment versus other large-cap biotechs?
Michel Vounatsos - Biogen Inc. - CEO & Director
Thank you, Phil. And before we begin, I would like to make -- to point out that I will be making some forward-looking statements, which are based on current